Chechirlian K, Messin M, Dantigny R, Economos G, Tete C, Perceau-Chambard E
Support Care Cancer. 2025; 33(2):126.
PMID: 39873852
DOI: 10.1007/s00520-025-09150-0.
Perea-Bello A, Trapero-Bertran M, Dursteler C
Diseases. 2024; 12(10).
PMID: 39452486
PMC: 11507158.
DOI: 10.3390/diseases12100243.
Rietze L, Stajduhar K, Purkis M, Cloutier D
Can J Nurs Res. 2024; 56(3):293-302.
PMID: 38576275
PMC: 11308282.
DOI: 10.1177/08445621241244532.
Perea-Bello A, Trapero-Bertran M, Dursteler C
Pharmacoeconomics. 2023; 42(3):301-318.
PMID: 38151673
PMC: 10861396.
DOI: 10.1007/s40273-023-01336-w.
Hillis C, Vicente C, Ball G
Pharmacoeconomics. 2022; 40(9):917-928.
PMID: 35844002
DOI: 10.1007/s40273-022-01169-z.
A multi-stage process to develop quality indicators for community-based palliative care using interRAI data.
Guthrie D, Williams N, Beach C, Buzath E, Cohen J, Declercq A
PLoS One. 2022; 17(4):e0266569.
PMID: 35390091
PMC: 8989210.
DOI: 10.1371/journal.pone.0266569.
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada.
Ball G, Lemieux C, Cameron D, Seftel M
Curr Oncol. 2022; 29(3):2021-2045.
PMID: 35323364
PMC: 8946986.
DOI: 10.3390/curroncol29030164.
Prognosis does not change the landscape: palliative home care clients experience high rates of pain and nausea, regardless of prognosis.
Williams N, Hermans K, Stevens T, Hirdes J, Declercq A, Cohen J
BMC Palliat Care. 2021; 20(1):165.
PMID: 34666732
PMC: 8527809.
DOI: 10.1186/s12904-021-00851-x.
How have casemix, cost and hospital stay of inpatients in the last year of life changed over the past decade? Evidence from Italy.
Berta P, Lovaglio P, Verzillo S
Health Policy. 2021; 125(8):1031-1039.
PMID: 34175137
PMC: 8310922.
DOI: 10.1016/j.healthpol.2021.06.005.
The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective.
Meyers B, Vogel A, Marotta P, Kavan P, Kamboj L, Pan J
Can J Gastroenterol Hepatol. 2021; 2021:8811018.
PMID: 33681090
PMC: 7929650.
DOI: 10.1155/2021/8811018.
Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada.
Younis T, Lee A, Coombes M, Bouganim N, Becker D, Revil C
Curr Oncol. 2020; 27(6):e578-e589.
PMID: 33380873
PMC: 7755445.
DOI: 10.3747/co.27.6517.
Potential quality indicators for seriously ill home care clients: a cross-sectional analysis using Resident Assessment Instrument for Home Care (RAI-HC) data for Ontario.
Harman L, Guthrie D, Cohen J, Declercq A, Fisher K, Goodridge D
BMC Palliat Care. 2019; 18(1):3.
PMID: 30626374
PMC: 6325754.
DOI: 10.1186/s12904-018-0389-y.
Geographical disparities in treatment and health care costs for end-of-life cancer patients in China: a retrospective study.
Leng A, Jing J, Nicholas S, Wang J
BMC Cancer. 2019; 19(1):39.
PMID: 30621633
PMC: 6325809.
DOI: 10.1186/s12885-018-5237-1.
Socioeconomic Differences in and Predictors of Home-Based Palliative Care Health Service Use in Ontario, Canada.
Cai J, Guerriere D, Zhao H, Coyte P
Int J Environ Res Public Health. 2017; 14(7).
PMID: 28718797
PMC: 5551240.
DOI: 10.3390/ijerph14070802.
What cost components are relevant for economic evaluations of palliative care, and what approaches are used to measure these costs? A systematic review.
Gardiner C, Ingleton C, Ryan T, Ward S, Gott M
Palliat Med. 2016; 31(4):323-337.
PMID: 27670418
PMC: 5405843.
DOI: 10.1177/0269216316670287.
Cost trajectories for cancer patients.
Wodchis W, Arthurs E, Khan A, Gandhi S, MacKinnon M, Sussman J
Curr Oncol. 2016; 23(Suppl 1):S64-75.
PMID: 26985150
PMC: 4780583.
DOI: 10.3747/co.23.2995.
End-of-Life Care Interventions: An Economic Analysis.
Pham B, Krahn M
Ont Health Technol Assess Ser. 2015; 14(18):1-70.
PMID: 26339303
PMC: 4552298.
Impact of aggressive management and palliative care on cancer costs in the final month of life.
Cheung M, Earle C, Rangrej J, Ho T, Liu N, Barbera L
Cancer. 2015; 121(18):3307-15.
PMID: 26031241
PMC: 4560956.
DOI: 10.1002/cncr.29485.
The health care cost of dying: a population-based retrospective cohort study of the last year of life in Ontario, Canada.
Tanuseputro P, Wodchis W, Fowler R, Walker P, Bai Y, Bronskill S
PLoS One. 2015; 10(3):e0121759.
PMID: 25811195
PMC: 4374686.
DOI: 10.1371/journal.pone.0121759.
Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute.
Choi Y, Keam B, Kim T, Lee S, Kim D, Heo D
Cancer Res Treat. 2015; 47(4):555-63.
PMID: 25687851
PMC: 4614190.
DOI: 10.4143/crt.2014.200.